Scholarlink

Objectives <p>While moderately hypofractionated radiotherapy (HFRT) has been recommended as the standard regimen in localized prostate cancer (LPCa) based on non-inferiority trials compared to conventionally fractionated radiotherapy(CFRT), the conclusions on its efficacy and toxicity have not been consistent among all trials. This study aims to systematically compare the efficacy and safety of HFRT with CFRT for LPCa based on the present randomized controlled trials. The longest follow-up data from all the trials were adopted.</p> Methods and materials <p>This research followed the steps outlined in the PRISMA statement for meta-analyses and systematic reviews. This study presents a meta-analysis of phase III trials comparing CFRT with HFRT for LPCa. The included trials reported relapse-free survival over five years and the incidence of acute or at least 3 years of late gastrointestinal (GI) and genitourinary (GU) toxicity.</p> Results <p>We were able to include 18 papers in our final analysis. There was no statistically significant difference in relapse-free survival after five years of treatment between the HFRT and CFRT groups. In subgroup analyses, with an α/β of 1.5, a higher equivalent dose of HFRT compared to CFRT is associated with improved relapse-free survival over five years. Acute GI toxicity of Grade 2 or worse was more common in the HFRT group compared to the CFRT group (<i>p</i> &lt; 0.00001). The incidence of acute GI toxicity of Grade 2 or worse rose by 8.78% when moderate HFRT was administered (95% CI = 4.69%-12.87%, <i>p</i> &lt; 0.0001). Subgroup analyses suggested that a single dose of 2.4–3.0&#xa0;Gy in HFRT may not contribute to an increase in acute GI complications. Moreover, in other outcomes, including acute GI toxicity Grade 3 or worse, acute GU toxicity, and late GI/GU toxicity, no significant differences were observed between the CFRT and HFRT groups.</p> Conclusion <p>The clinical outcomes of HFRT and CFRT were comparable, with similar five-year relapse-free survival, and without different risks of acute or late, severe GI or GU toxicity. HFRT treatment may increase the risk of Grade 2 or worse acute GI toxicity. Thus, proper monitoring and management are required. Less than 3.0&#xa0;Gy of a single dose or a lower α/β value may be worth considering in the HFRT scheme. Further comprehensive examination of the findings in subgroup analyses is required, such as appropriate dose ranges and management of acute toxicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of the safety and efficacy of moderately hypofractionated and conventionally fractionated radiotherapy for localized prostate cancer: evidence from 9074 men in 13 randomized clinical trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月23日

查看全文
  • Huizhu Chen,
  • Jiayan Chen,
  • Feng Lyu,
  • Mingwei Ma,
  • Xin Qi,
  • Xueying Ren,
  • Shangbin Qin,
  • Xiaomei Li,
  • Xiaoying Li,
  • Xiaobin Gu,
  • Xueying Li,
  • Hongzhen Li,
  • Xianshu Gao

摘要

Objectives

While moderately hypofractionated radiotherapy (HFRT) has been recommended as the standard regimen in localized prostate cancer (LPCa) based on non-inferiority trials compared to conventionally fractionated radiotherapy(CFRT), the conclusions on its efficacy and toxicity have not been consistent among all trials. This study aims to systematically compare the efficacy and safety of HFRT with CFRT for LPCa based on the present randomized controlled trials. The longest follow-up data from all the trials were adopted.

Methods and materials

This research followed the steps outlined in the PRISMA statement for meta-analyses and systematic reviews. This study presents a meta-analysis of phase III trials comparing CFRT with HFRT for LPCa. The included trials reported relapse-free survival over five years and the incidence of acute or at least 3 years of late gastrointestinal (GI) and genitourinary (GU) toxicity.

Results

We were able to include 18 papers in our final analysis. There was no statistically significant difference in relapse-free survival after five years of treatment between the HFRT and CFRT groups. In subgroup analyses, with an α/β of 1.5, a higher equivalent dose of HFRT compared to CFRT is associated with improved relapse-free survival over five years. Acute GI toxicity of Grade 2 or worse was more common in the HFRT group compared to the CFRT group (p < 0.00001). The incidence of acute GI toxicity of Grade 2 or worse rose by 8.78% when moderate HFRT was administered (95% CI = 4.69%-12.87%, p < 0.0001). Subgroup analyses suggested that a single dose of 2.4–3.0 Gy in HFRT may not contribute to an increase in acute GI complications. Moreover, in other outcomes, including acute GI toxicity Grade 3 or worse, acute GU toxicity, and late GI/GU toxicity, no significant differences were observed between the CFRT and HFRT groups.

Conclusion

The clinical outcomes of HFRT and CFRT were comparable, with similar five-year relapse-free survival, and without different risks of acute or late, severe GI or GU toxicity. HFRT treatment may increase the risk of Grade 2 or worse acute GI toxicity. Thus, proper monitoring and management are required. Less than 3.0 Gy of a single dose or a lower α/β value may be worth considering in the HFRT scheme. Further comprehensive examination of the findings in subgroup analyses is required, such as appropriate dose ranges and management of acute toxicity.